Numerous studies have demonstrated the efficacy of blocking PD-1 or PD-L1 with specific antibodies, especially in breast cancer, where metastatic triple-negative breast cancer (TNBC) has shown promising responses [87]. Here, CD274 is linked to breast carcinoma.